These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 25219883)

  • 21. Melatonin, bone regulation and the ubiquitin-proteasome connection: A review.
    Vriend J; Reiter RJ
    Life Sci; 2016 Jan; 145():152-60. PubMed ID: 26706287
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bortezomib abolishes tumor necrosis factor-related apoptosis-inducing ligand resistance via a p21-dependent mechanism in human bladder and prostate cancer cells.
    Lashinger LM; Zhu K; Williams SA; Shrader M; Dinney CP; McConkey DJ
    Cancer Res; 2005 Jun; 65(11):4902-8. PubMed ID: 15930312
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Reduction in BCL-2 levels by 26S proteasome inhibition with bortezomib is associated with induction of apoptosis in small cell lung cancer.
    Mortenson MM; Schlieman MG; Virudachalam S; Lara PN; Gandara DG; Davies AM; Bold RJ
    Lung Cancer; 2005 Aug; 49(2):163-70. PubMed ID: 16022909
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Bortezomib induces caspase-dependent apoptosis in Hodgkin lymphoma cell lines and is associated with reduced c-FLIP expression: a gene expression profiling study with implications for potential combination therapies.
    Zhao X; Qiu W; Kung J; Zhao X; Peng X; Yegappan M; Yen-Lieberman B; Hsi ED
    Leuk Res; 2008 Feb; 32(2):275-85. PubMed ID: 17659339
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Proteasome inhibition induces hepatic stellate cell apoptosis.
    Anan A; Baskin-Bey ES; Bronk SF; Werneburg NW; Shah VH; Gores GJ
    Hepatology; 2006 Feb; 43(2):335-44. PubMed ID: 16440346
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Anti-tumor activity of the proteasome inhibitor bortezomib in gastric cancer.
    Nakata W; Hayakawa Y; Nakagawa H; Sakamoto K; Kinoshita H; Takahashi R; Hirata Y; Maeda S; Koike K
    Int J Oncol; 2011 Dec; 39(6):1529-36. PubMed ID: 21785822
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The proteasome inhibitor bortezomib disrupts tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) expression and natural killer (NK) cell killing of TRAIL receptor-positive multiple myeloma cells.
    Feng X; Yan J; Wang Y; Zierath JR; Nordenskjöld M; Henter JI; Fadeel B; Zheng C
    Mol Immunol; 2010 Aug; 47(14):2388-96. PubMed ID: 20542572
    [TBL] [Abstract][Full Text] [Related]  

  • 28. JNK and AP-1 mediate apoptosis induced by bortezomib in HepG2 cells via FasL/caspase-8 and mitochondria-dependent pathways.
    Lauricella M; Emanuele S; D'Anneo A; Calvaruso G; Vassallo B; Carlisi D; Portanova P; Vento R; Tesoriere G
    Apoptosis; 2006 Apr; 11(4):607-25. PubMed ID: 16528474
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The proteasome inhibitor PS-341 (bortezomib) up-regulates DR5 expression leading to induction of apoptosis and enhancement of TRAIL-induced apoptosis despite up-regulation of c-FLIP and survivin expression in human NSCLC cells.
    Liu X; Yue P; Chen S; Hu L; Lonial S; Khuri FR; Sun SY
    Cancer Res; 2007 May; 67(10):4981-8. PubMed ID: 17510429
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Bortezomib sensitizes primary human astrocytoma cells of WHO grades I to IV for tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis.
    Koschny R; Holland H; Sykora J; Haas TL; Sprick MR; Ganten TM; Krupp W; Bauer M; Ahnert P; Meixensberger J; Walczak H
    Clin Cancer Res; 2007 Jun; 13(11):3403-12. PubMed ID: 17545549
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Extensive immunoglobulin production sensitizes myeloma cells for proteasome inhibition.
    Meister S; Schubert U; Neubert K; Herrmann K; Burger R; Gramatzki M; Hahn S; Schreiber S; Wilhelm S; Herrmann M; Jäck HM; Voll RE
    Cancer Res; 2007 Feb; 67(4):1783-92. PubMed ID: 17308121
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Targeting BCL-2 overexpression in various human malignancies through NF-kappaB inhibition by the proteasome inhibitor bortezomib.
    Fahy BN; Schlieman MG; Mortenson MM; Virudachalam S; Bold RJ
    Cancer Chemother Pharmacol; 2005 Jul; 56(1):46-54. PubMed ID: 15791457
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Differential sensitivity of breast cancer and melanoma cells to proteasome inhibitor Velcade.
    Yerlikaya A; Erin N
    Int J Mol Med; 2008 Dec; 22(6):817-23. PubMed ID: 19020781
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The proteasome inhibitor PS-341 overcomes TRAIL resistance in Bax and caspase 9-negative or Bcl-xL overexpressing cells.
    Johnson TR; Stone K; Nikrad M; Yeh T; Zong WX; Thompson CB; Nesterov A; Kraft AS
    Oncogene; 2003 Aug; 22(32):4953-63. PubMed ID: 12902978
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Novel proteasome inhibitors to overcome bortezomib resistance.
    Ruschak AM; Slassi M; Kay LE; Schimmer AD
    J Natl Cancer Inst; 2011 Jul; 103(13):1007-17. PubMed ID: 21606441
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The protective effects of the proteasome inhibitor bortezomib (velcade) on ischemia-reperfusion injury in the rat retina.
    Chen FT; Yang CM; Yang CH
    PLoS One; 2013; 8(5):e64262. PubMed ID: 23691186
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Inhibition of proteasome activity, nuclear factor-KappaB translocation and cell survival by the antialcoholism drug disulfiram.
    Lövborg H; Oberg F; Rickardson L; Gullbo J; Nygren P; Larsson R
    Int J Cancer; 2006 Mar; 118(6):1577-80. PubMed ID: 16206267
    [TBL] [Abstract][Full Text] [Related]  

  • 38. MicroRNA-101 Suppresses Tumor Cell Proliferation by Acting as an Endogenous Proteasome Inhibitor via Targeting the Proteasome Assembly Factor POMP.
    Zhang X; Schulz R; Edmunds S; Krüger E; Markert E; Gaedcke J; Cormet-Boyaka E; Ghadimi M; Beissbarth T; Levine AJ; Moll UM; Dobbelstein M
    Mol Cell; 2015 Jul; 59(2):243-57. PubMed ID: 26145175
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A proteomic analysis of p53-independent induction of apoptosis by bortezomib in 4T1 breast cancer cell line.
    Yerlikaya A; Okur E; Baykal AT; Acılan C; Boyacı I; Ulukaya E
    J Proteomics; 2015 Jan; 113():315-25. PubMed ID: 25305590
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Proteasome inhibition induces both antioxidant and hb f responses in sickle cell disease via the nrf2 pathway.
    Pullarkat V; Meng Z; Tahara SM; Johnson CS; Kalra VK
    Hemoglobin; 2014; 38(3):188-95. PubMed ID: 24670032
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.